ipamorelin clinical trial 2025 + CJC-1295 (No DAC) Bundle — 2 Vials 16th Annual Clinical Trials Summit
Description
A median duration of response of 10 months and a median progression-free survival of 6.8 months were also confirmed, in line with earlier Phase I results
doi: 10.1073/pnas.2000430117
Stroke 42:33233328
This increase in cytokine production further increases oxidative stress which in turn affects mitochondrial functioning and disrupts the production of ATP
